Search: id:"swepub:oai:DiVA.org:uu-319650" >
Early BCR-ABL1 Tran...
-
El Missiry, MohamedUniv Helsinki, Hematol Res Unit Helsinki, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland.
(author)
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
2017-01-30
-
PUBLIC LIBRARY SCIENCE,2017
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-319650
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-319650URI
-
https://doi.org/10.1371/journal.pone.0171041DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:135282804URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
In chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of tyrosine kinase inhibitor (TKI) treatment to predict therapy response. Fifty-two first-line TKI-treated CML patients were included (imatinib n = 26, dasatinib n = 21, nilotinib n = 5), and BCR-ABL1 transcript levels were measured at diagnosis (dg) and 1, 3, 6, 12, 18, 24, and 36 months. The fold change of the BCR-ABL1 transcripts at 1 month compared to initial BCR-ABL1 transcript levels was used to indicate early therapy response. In our cohort, 21% of patients had no decrease in BCR-ABL1 transcript levels after 1 month and were classified as poor responders. Surprisingly, these patients had lower BCR-ABL1 transcript levels at dg compared to responders (31% vs. 48%, p = 0.0083). Poor responders also significantly more often had enlarged spleen (55% vs. 15%; p< 0.01) and a higher percentage of Ph+ CD34+CD38- cells in the bone marrow (91% vs. 75%, p< 0.05). The major molecular response rates were inferior in the poor responders (at 12m 18% vs. 64%, p< 0.01; 18m 27% vs. 75%, p< 0.01; 24m 55% vs. 87%, p< 0.01). In conclusion, early treatment response analysis defines a biologically distinct patient subgroup with inferior long-term outcomes.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Hjorth-Hansen, HenrikSt Olavs Hosp, Dept Hematol, Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, St Olavs Hosp, Dept Canc Res & Mol Med, Trondheim, Norway.
(author)
-
Richter, JohanSkane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden.
(author)
-
Olsson-Strömberg, UllaUppsala universitet,Hematologi(Swepub:uu)ulols170
(author)
-
Stenke, LeifKarolinska Institutet
(author)
-
Porkka, KimmoUniv Helsinki, Hematol Res Unit Helsinki, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland.
(author)
-
Kreutzman, AnnaUniv Helsinki, Hematol Res Unit Helsinki, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland.
(author)
-
Mustjoki, SatuUniv Helsinki, Hematol Res Unit Helsinki, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland.;Univ Helsinki, Dept Clin Chem, Helsinki, Finland.
(author)
-
Univ Helsinki, Hematol Res Unit Helsinki, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland.St Olavs Hosp, Dept Hematol, Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, St Olavs Hosp, Dept Canc Res & Mol Med, Trondheim, Norway.
(creator_code:org_t)
Related titles
-
In:PLOS ONE: PUBLIC LIBRARY SCIENCE12:11932-6203
Internet link
Find in a library
-
PLOS ONE
(Search for host publication in LIBRIS)
To the university's database